/AXSM

AXSM Stock - Axsome Therapeutics, Inc.

Q: What is the analyst price target for AXSM?

Analyst price target information is not currently available for AXSM.

Q: What is AXSM's market cap?

Market capitalization information is not currently available for AXSM.

Healthcare|Biotechnology|NASDAQ

$174.33-1.41%

$2.49 (-1.41%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+16.8%upside

Target: $203.62

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AXSM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.43

52W High$184.40

52W Low$86.06

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$385.69M	$270.60M	$50.04M	N/A	N/A
Gross Profit	$352.39M	$244.53M	$44.84M	N/A	N/A
Gross Margin	91.4%	90.4%	89.6%	N/A	N/A
Operating Income	$-280,562,000	$-231,825,000	$-179,799,000	$-124,707,000	$-99,141,328
Net Income	$-287,216,000	$-239,238,000	$-187,134,000	$-130,403,000	$-102,900,600
Net Margin	-74.5%	-88.4%	-374.0%	N/A	N/A
EPS	$-5.99	$-5.27	$-4.60	$-3.47	$-2.83

Company Overview

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Visit Website

Earnings History & Surprises

AXSM

Beat Rate

78%

Last 18 quarters

Avg Surprise

+11.3%

EPS vs Estimate

Beats / Misses

14/4

Last 12 quarters

Latest EPS

$-0.94

Q4 2025

EPS Surprise History

Q1 24

+39.7%

$-0.73vs$-1.21

Q2 24

+9.2%

$-1.09vs$-1.20

Q3 24

+4.6%

$-1.24vs$-1.30

Q4 24

+2.9%

$-1.34vs$-1.38

Q1 25

+4.0%

$-0.96vs$-1.00

Q2 25

+36.5%

$-0.80vs$-1.26

Q3 25

+8.0%

$-0.92vs$-1.00

Q4 25

-14.6%

$-0.94vs$-0.82

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 4, 2026	—	—	—	—
Q1 2026	Feb 17, 2026	$-0.76	—	—	—
Q4 2025	Nov 3, 2025	$-0.82	$-0.94	-14.6%	✗ MISS
Q3 2025	Aug 4, 2025	$-1.00	$-0.92	+8.0%	✓ BEAT
Q2 2025	May 5, 2025	$-1.26	$-0.80	+36.5%	✓ BEAT
Q1 2025	Feb 18, 2025	$-1.00	$-0.96	+4.0%	✓ BEAT
Q4 2024	Nov 12, 2024	$-1.38	$-1.34	+2.9%	✓ BEAT
Q3 2024	Aug 5, 2024	$-1.30	$-1.24	+4.6%	✓ BEAT
Q2 2024	May 6, 2024	$-1.20	$-1.09	+9.2%	✓ BEAT
Q1 2024	Feb 20, 2024	$-1.21	$-0.73	+39.7%	✓ BEAT
Q4 2023	Nov 6, 2023	$-1.24	$-1.32	-6.5%	✗ MISS
Q3 2023	Aug 7, 2023	$-1.24	$-1.00	+19.4%	✓ BEAT
Q2 2023	May 8, 2023	$-1.13	$-0.22	+80.5%	✓ BEAT
Q1 2023	Feb 27, 2023	$-1.18	$-1.28	-8.5%	✗ MISS
Q4 2022	Nov 7, 2022	$-1.10	$-1.03	+6.4%	✓ BEAT
Q3 2022	Aug 9, 2022	$-1.19	$-1.06	+10.9%	✓ BEAT
Q2 2022	May 2, 2022	$-1.02	$-1.03	-1.0%	✗ MISS
Q1 2022	Mar 1, 2022	$-0.99	$-0.90	+9.1%	✓ BEAT
Q4 2021	Nov 8, 2021	$-0.94	$-0.93	+1.1%	✓ BEAT
Q3 2021	Aug 9, 2021	$-0.88	$-0.86	+2.3%	✓ BEAT

Frequently Asked Questions about AXSM

What is AXSM's current stock price?

Axsome Therapeutics, Inc. (AXSM) is currently trading at $174.33 per share. The stock has moved -1.41% today.

What is the analyst price target for AXSM?

The average analyst price target for AXSM is $203.64, based on 1 analyst.

What sector is Axsome Therapeutics, Inc. in?

Axsome Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is AXSM's market cap?

Axsome Therapeutics, Inc. has a market capitalization of $8.79 billion, making it a mid-cap company.

Does AXSM pay dividends?

No, Axsome Therapeutics, Inc. does not currently pay a dividend to shareholders.